Dublin, Dec. 13, 2018 (GLOBE NEWSWIRE) -- The "Cancer Vaccines: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.

With the first prophylactic cancer vaccine Gardasil approved in 2006 and therapeutic cancer vaccine Sipuleucel-T (Provenge) approved in 2010, cancer vaccines is a proven hot treatment modality which is now turbocharged with the event of immune-checkpoint inhibitors.

Cancer Vaccines: Analytical Tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of immune-oncology. This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your cancer vaccine drug surveillance and intelligence, allowing you to power your decision making and advance your own interests.

Keeping you In the know
Simply put, our mission is to fuel your knowledge of immune-oncology, to make you the first to know about very early technologies and startups, emerging clinical trial results, drug approvals and the ever-changing competitive landscape.

Cancer Vaccines: Analytical Tool achieves this by continuously scanning development in cancer vaccine and reporting:

• Deals & Collaborations
• New technologies/drugs (emerging from patents, grants, abstracts (see Conference Coverage) etc.)
• Funding/Grants/IPOs
• Filings & Approvals
• Latest Clinical Trial Development & Results
• Newly launched clinical trials
• Conference Coverage of the world's twelve leading meetings in oncology*
• Quarterly & Annual Reporting

This puts you in control of most, if not all, day-to-day developments in your field while also benefiting from one of the most comprehensive commercial pipeline review & competitive assessment tools available on the market today!

Identify, prioritize, and lead scientific assessment of oncology opportunities and competition by multiple factors such as:

• Emerging Technologies
• Target Novelty
• Recent Funding
• Early & Late Stage Pipeline
• Biomarker/Companion Diagnostic Development (featured below)
• Entered Deals & Alliances
• Conference surveillance of world leading cancer meetings (featured below)
• Combination Therapy Choices (featured below)
• Outcome of Clinical Trials
• Indication Selection & Expansion Choices
• Drug Repositioning Opportunities

For 20 years we have supported better decision making across the oncology drug development industry. Your Cancer Vaccines: Analytical Tool is based on two decades of proven methodology and transforms your computer's desktop into a high capacity workbench within your area of choice. Even before launching this tool you have already eliminated the hundreds of hours of work needed to discover, process and piece together the thousands of sources that our team of oncology dedicated and highly experienced contents specialists have done on your behalf.

Your Cancer Vaccines: Analytical Tool covers more than 372 companies plus partners who are today developing 767 cancer vaccine drugs where of 482 are in active development in cancer across 211 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.

For more information about this report visit https://www.researchandmarkets.com/research/mz4vzj/cancer_vaccines?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Cancer Vaccines

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.